COVID-19 Human IgA ELISA kit (Nucleocapsid Protein)

Measurement method : Indirect ELISA
Measurement wavelength : 450 nm
Measurement sample : Serum, saliva, sputum
Species reactivity : Human
Storage temperature : Store at 2-8° C. 
Expiration date : 12 months after production
Immobilized antigen : SARS-CoV-2 Nucleocapsid protein (Full length, E. coli expression system)

1. SARS-CoV-2 nucleocapsid protein-immobilized plate

2. HRP-conjugated anti-human IgA antibody

3. Washing buffer（10× PBST）

4. Bovine serum albumin (for diluent buffer)

5. Diluent buffer (10×)

6. R-1: Chromogenic substrate (TMB)

7. R-2: Stop reagent (1 mol/L hydrochloric acid)

8. Microplate seal

×1

10 μL×1

100 mL×1

×1

50 mL×1

22 mL×1

22 mL×1

×2

1. The SARS-CoV-2 recombinant nucleocapsid protein immobilized on the plate is recognized and reacted with the antibody (hereinafter, abbreviated as anti-nucleocapsid protein antibody) in a sample.

2.  After the reaction, the sample is removed by washing

3.  The anti-spike protein antibody is reacted with HRP (Horseradish peroxidase)-conjugated anti-human IgA antibody

4. Remove excess HRP-conjugated anti-human IgA antibody by washing. Add a chromogenic substrate and measure the absorbance.

This kit is a research ELISA kit to detect human IgA antibody that recognizes the nucleocapsid protein of SARS-CoV-2, the causative virus of Covid-19.
Virus detection can be broadly divided into two approaches: one is to detect the virus itself, such as PCR method, and the other is to detect the immune response that develops during infection (IgG, IgM, IgA). IgA is particularly abundant in mucous membranes such as saliva and the nasopharynx, and generally has the function of infection prevention.

• Daniel K. Jin et al.
  Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”​

      PLoS One. 2021 Apr. PubMed PMID: 33909646

• Helena Cerutti et al.
  Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development​

      J Clin Lab Anal. 2021 Feb. PubMed PMID: 33608968

• Silvano Wendel et al.
  Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program​

      Transfusion. 2020 Dec. PubMed PMID: 32935877

• Larry L. Luchsinger et al.
  Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients​

      J Clin Microbiol. 2020 Dec. PubMed PMID: 32917729

• Melanie A. MacMullan et al.
  ELISA detection of SARS-CoV-2 antibodies in saliva​

      Sci Rep. 2020 Nov. PubMed PMID: 33257702

• Sonny Elizaldi et al.
  SARS-CoV-2 infection induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques

      Res Sq. 2020 Aug 14. PubMed PMID: 32818217​​

• Jonathan J Deeks et al.
  Antibody tests for identification of current and past infection with SARS-CoV-2

      Cochrane Database Syst Rev. 2020 Jun 25. PubMed PMID: 32584464​

• Nadin Younes et al.
  Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2

     Viruses. 2020 May 26. PubMed PMID: 32466458​​

1.)Keiichi Hiramatsu, Standard Textbook of standard microbiology, 11th edition, Medical study (2012)

2.)Andrea Padoan, IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study, Clinica Chimica Acta, 507, 164-166, Aug., 2020

3.)Yin Xia Chao, The role of IgA in COVID-19, Brain, Behavior, and Immunity, 87, Jul., 2020 

​